Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma

Inclusion Criteria

• •Histologically proven, newly diagnosed IDH wildtype glioblastoma (GBM) that has a methylated MGMT promoter as assessed by the standardized institutional analysis.
• •Patients must be receiving TMZ as part of their standard adjuvant treatment regimen following treatment with TMZ and Radiation.
• •Patients must have a Karnofsky performance ≥ 60%.
• •Normal organ function as follows:
• •* Absolute Neutrophil Count (ANC) ≥ 1.0 x 10\^9/ L
• •* Platelets ≥ 100 x 10\^9 / L
• •* Hemoglobin ≥ 8.0 g / dL
• •Age 18 years or older.
• •Kidney function (creatinine level within normal institutional limit, or creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine level above institutional normal).
• •Liver function (AST/ALT \<2.5 X institutional upper limit of normal (ULN), Total bilirubin ≤ 1.5 times ULN, INR within 1.5 times ULN (or if receiving anticoagulant therapy an INR of ≤ 3.0 is allowed with concomitant increase in PT or an aPTT ≤ 2.5 × control).
• •Women able to become pregnant must have a negative pregnancy test within 30 days of registration.
• •Patients must have the ability to understand and the willingness to sign a written informed consent document.